BlackBarn Capital Partners LP Has $22.57 Million Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

BlackBarn Capital Partners LP boosted its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 18.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,850,000 shares of the company's stock after purchasing an additional 438,388 shares during the quarter. Amneal Pharmaceuticals comprises 1.2% of BlackBarn Capital Partners LP's holdings, making the stock its 5th biggest position. BlackBarn Capital Partners LP owned 0.92% of Amneal Pharmaceuticals worth $22,572,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. JPMorgan Chase & Co. increased its stake in Amneal Pharmaceuticals by 149.7% in the third quarter. JPMorgan Chase & Co. now owns 1,297,094 shares of the company's stock valued at $10,792,000 after purchasing an additional 777,568 shares in the last quarter. Mariner LLC grew its holdings in shares of Amneal Pharmaceuticals by 3,749.1% in the 4th quarter. Mariner LLC now owns 424,291 shares of the company's stock valued at $3,360,000 after buying an additional 413,268 shares during the period. Geode Capital Management LLC increased its position in shares of Amneal Pharmaceuticals by 11.1% in the 3rd quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company's stock valued at $31,511,000 after buying an additional 378,136 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Amneal Pharmaceuticals in the 4th quarter valued at $2,946,000. Finally, Dimensional Fund Advisors LP raised its stake in Amneal Pharmaceuticals by 5.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 4,991,702 shares of the company's stock worth $39,531,000 after buying an additional 278,653 shares during the period. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Trading Up 0.8 %

Shares of Amneal Pharmaceuticals stock traded up $0.06 during trading on Friday, reaching $7.48. The stock had a trading volume of 1,775,605 shares, compared to its average volume of 1,397,424. The company has a market capitalization of $2.32 billion, a price-to-earnings ratio of -11.00 and a beta of 1.06. The stock has a fifty day moving average price of $8.06 and a two-hundred day moving average price of $8.21. Amneal Pharmaceuticals, Inc. has a 52 week low of $5.81 and a 52 week high of $9.48.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its earnings results on Friday, February 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.03). The firm had revenue of $730.52 million during the quarter, compared to the consensus estimate of $708.21 million. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. During the same quarter in the previous year, the firm posted $0.14 EPS. On average, equities analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Analysts Set New Price Targets

AMRX has been the topic of a number of research analyst reports. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and raised their price target for the stock from $9.00 to $12.00 in a research report on Monday, February 24th. Barclays raised their target price on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a report on Monday, March 3rd. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $10.80.

Insiders Place Their Bets

In other news, Director Gautam Patel sold 80,000 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.90, for a total transaction of $712,000.00. Following the sale, the director now owns 1,808,886 shares in the company, valued at $16,099,085.40. This represents a 4.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the firm's stock in a transaction on Friday, March 14th. The shares were sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the completion of the transaction, the insider now directly owns 48,578,209 shares of the company's stock, valued at $405,628,045.15. This represents a 9.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,160,000 shares of company stock valued at $43,113,200 in the last three months. 17.45% of the stock is currently owned by corporate insiders.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.